Company research
Cartesian Therapeutics, Inc.
CIK 1453687Updated Nov 9, 2026
RNAC price & chart
Loading TradingView…
NASDAQ:RNAC on TradingView ↗About the company
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
In the news
Cartesian Therapeutics to Participate in Upcoming Investor Conferences ↗
Seeking Alpha
Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement ↗
Adicet Bio: A Cheap Gamma Delta T-Cell Play ↗
Cartesian Therapeutics EPS of $0.46 ↗
SEC disclosures
Cartesian Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
SCHEDULE 13G/A - filed by BARCLAYS PLC regarding Cartesian Therapeutics, Inc.
10-Q filing
8-K filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
144 filing
Regulation FD Disclosure
Items 7.01, 9.01
144 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 372,675,000Source | 455,316,000Source | 318,628,000Source | 388,893,000Source | 347,738,000Source | 288,391,000Source | 409,130,000Source | 325,207,000Source | 296,411,000Source | 435,023,000Source | 305,050,000Source | 165,886,000Source |
| Property, Plant and Equipment, NetUSD | 12,394,000Source | 10,225,000Source | 11,311,000Source | 12,285,000Source | 6,672,000Source | 11,637,000Source | 10,174,000Source | 2,402,000Source | 12,185,000Source | 9,912,000Source | 2,113,000Source | 2,794,000Source |
| GoodwillUSD | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 143,384,000Source | 219,198,000Source | 147,606,000Source | 160,324,000Source | 87,227,000Source | 118,641,000Source | 180,434,000Source | 103,418,000Source | 125,139,000Source | 212,610,000Source | 76,911,000Source | 106,438,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 722,000Source | 4,829,000Source | 196,000Source | 354,000Source | 32,039,000Source | 261,000Source | 1,765,000Source | 2,006,000Source | 1,115,000Source | 872,000Source | 5,870,000Source | 6,596,000Source |
| Assets, CurrentUSD | 147,260,000Source | 229,136,000Source | 153,615,000Source | 163,395,000Source | 124,782,000Source | 122,039,000Source | 185,120,000Source | 111,109,000Source | 129,276,000Source | 216,626,000Source | 90,729,000Source | 148,138,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,154,000Source | 4,129,000Source | 5,813,000Source | 2,717,000Source | 2,044,000Source | 3,137,000Source | 2,921,000Source | 3,315,000Source | 3,022,000Source | 3,144,000Source | 4,967,000Source | 3,778,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,972,000Source | 13,523,000Source | 5,124,000Source | 5,164,000Source | 13,852,000Source | 5,366,000Source | 5,351,000Source | 9,556,000Source | 5,601,000Source | 5,535,000Source | 10,068,000Source | 11,617,000Source |
| Other Assets, NoncurrentUSD | — | — | — | 5,551,000Source | — | — | 6,053,000Source | — | — | 518,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 408,519,000Source | 454,564,000Source | 443,854,000Source | 391,420,000Source | 449,196,000Source | 436,509,000Source | 430,919,000Source | 442,007,000Source | 422,651,000Source | 441,825,000Source | 444,680,000Source | 72,058,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 3,000Source | 3,000Source | 2,000Source | 3,000Source | 3,000Source | 1,000Source | 3,000Source | 3,000Source | 16,000Source | 15,000Source |
| Additional Paid in CapitalUSD | 698,537,000Source | 687,174,000Source | 725,165,000Source | 695,942,000Source | 560,766,000Source | 718,017,000Source | 692,578,000Source | 559,275,000Source | 700,706,000Source | 689,887,000Source | 179,047,000Source | 493,308,000Source |
| Retained Earnings (Accumulated Deficit)USD | -729,797,000Source | -681,818,000Source | -845,786,000Source | -693,895,000Source | -657,635,000Source | -861,555,000Source | -709,781,000Source | -671,471,000Source | -822,373,000Source | -692,071,000Source | -614,647,000Source | -394,937,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,587,000Source | -4,606,000Source | -4,608,000Source | -4,577,000Source | -4,591,000Source | -4,583,000Source | -4,589,000Source | -4,605,000Source | -4,576,000Source | -4,621,000Source | -4,600,000Source | -4,558,000Source |
| Stockholders' Equity Attributable to ParentUSD | -35,844,000Source | 752,000Source | -125,226,000Source | -2,527,000Source | -101,458,000Source | -148,118,000Source | -21,789,000Source | -116,800,000Source | -126,240,000Source | -6,802,000Source | -440,184,000Source | 93,828,000Source |
| Liabilities and EquityUSD | 372,675,000Source | 455,316,000Source | 318,628,000Source | 388,893,000Source | 347,738,000Source | 288,391,000Source | 409,130,000Source | 325,207,000Source | 296,411,000Source | 435,023,000Source | 305,050,000Source | 165,886,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 13,803,000Source | 21,405,000Source | 20,550,000Source | 12,256,000Source | 26,115,000Source | 15,945,000Source | 14,998,000Source | 36,654,000Source | 14,937,000Source | 22,976,000Source | 68,209,000Source | 25,077,000Source |
| Operating Lease, Liability, CurrentUSD | 3,876,000Source | 2,770,000Source | 4,197,000Source | 3,790,000Source | 2,523,000Source | 4,186,000Source | 3,704,000Source | 2,229,000Source | 4,151,000Source | 2,851,000Source | 2,166,000Source | 1,608,000Source |
| Accounts Payable, CurrentUSD | 2,225,000Source | 517,000Source | 1,046,000Source | 454,000Source | 2,862,000Source | 1,598,000Source | 2,097,000Source | 2,517,000Source | 1,288,000Source | 288,000Source | 3,150,000Source | 316,000Source |
| Operating Lease, Liability, NoncurrentUSD | 8,727,000Source | 11,881,000Source | 6,805,000Source | 9,559,000Source | 12,344,000Source | 7,669,000Source | 10,362,000Source | 8,228,000Source | 8,525,000Source | 11,133,000Source | 8,789,000Source | 10,055,000Source |
| Deferred Income Tax Liabilities, NetUSD | 16,141,000Source | 15,853,000Source | 6,948,000Source | 16,141,000Source | 15,853,000Source | 6,948,000Source | 16,141,000Source | 15,853,000Source | 6,948,000Source | 16,141,000Source | 15,853,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,702,000Source | 9,363,000Source | 15,142,000Source | 8,012,000Source | 10,615,000Source | 10,161,000Source | 9,197,000Source | 8,927,000Source | 9,498,000Source | 12,076,000Source | 14,733,000Source | 14,084,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 6,948,000Source | 16,140,000Source | 15,853,000Source | — |
| Long-term Debt, Excluding Current Maturities | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,423,000Source | 2,508,000Source | 10,521,000Source | 6,582,000Source | 22,524,000Source | 11,194,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -854,000Source | 893,000Source | 243,000Source | -4,998,000Source | -726,000Source | -3,318,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 310,000Source | 1,819,000Source | 1,066,000Source | -2,927,000Source | 2,834,000Source | 92,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -9,193,000Source | 287,000Source | -19,000,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -22,135,000Source | -23,108,000Source | -73,941,000Source | -23,674,000Source | -51,161,000Source | -31,631,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -27,000Source | -1,075,000Source | -5,454,000Source | -8,742,000Source | 34,609,000Source | -15,002,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 27,000Source | 1,075,000Source | 5,454,000Source | 9,093,000Source | 206,000Source | 1,201,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 15,671,000Source | -8,025,000Source | -8,055,000Source | 168,428,000Source | -13,145,000Source | 39,215,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 27,457,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -6,498,000Source | -32,176,000Source | -87,405,000Source | 135,991,000Source | -29,750,000Source | -7,398,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 145,119,000Source | 220,867,000Source | 149,341,000Source | 162,059,000Source | 120,376,000Source | 182,103,000Source | 126,874,000Source | 214,279,000Source | 78,288,000Source | 108,038,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,853,000Source | 2,248,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -7,000Source | 32,000Source | 45,000Source | -21,000Source | -53,000Source | 20,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,590,000Source | 1,695,000Source | 2,083,000Source | 3,279,000Source | 2,423,000Source | 2,508,000Source | 10,521,000Source | 6,582,000Source | 25,778,000Source | 11,194,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | — | — | -110,000Source |
| DepreciationUSD | — | — | 600,000Source | 300,000Source | 800,000Source | 600,000Source | 600,000Source | 600,000Source | 2,400,000Source | 1,200,000Source | 700,000Source | 700,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | — | — | — | — | — | — | — | — | 2,000,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 38,000Source | -22,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -6,890,000Source | -149,600,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | 0Source | 0Source | -273,000Source | -477,000Source | 147,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | -740,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 7,716,000Source | 6,562,000Source | 8,724,000Source | 7,240,000Source | 7,114,000Source | 8,315,000Source | 31,468,000Source | 30,126,000Source | 40,581,000Source | 23,862,000Source |
| GoodwillUSD | — | — | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | 48,163,000Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 56,700,000Source | — | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -9,193,000Source | 287,000Source | -19,000,000Source | -609,000Source |
| InterestExpenseNonoperatingUSD | — | — | — | 0Source | 852,000Source | 0Source | — | — | — | 0Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | 1,103,000Source | 1,748,000Source | 1,026,000Source | 2,015,000Source | 6,579,000Source | 7,386,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -35,902,000Source | -24,183,000Source | 15,769,000Source | 15,886,000Source | -39,182,000Source | -17,710,000Source | -130,302,000Source | -77,424,000Source | -219,710,000Source | 35,379,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | 13,720,000Source | 13,258,000Source | — | — | -130,302,000Source | -77,424,000Source | -257,260,000Source | — |
| Nonoperating Income (Expense)USD | — | — | — | — | 44,924,000Source | 37,697,000Source | -12,683,000Source | 4,179,000Source | 3,910,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 21,518,000Source | 17,962,000Source | 29,155,000Source | 22,109,000Source | 26,577,000Source | 22,989,000Source | 146,202,000Source | 82,810,000Source | 112,420,000Source | 96,239,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 7,400,000Source | 710,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 250,000Source | 126,000Source | -5,000Source | -3,000Source | 0Source | -2,010,000Source | 606,000Source | 691,000Source | 330,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 15,392,000Source | 0Source | — | — | — | 2,121,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | 0Source | 28,254,000Source | 19,700,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 279,000Source | 183,000Source | 323,000Source | 1,179,000Source | 0Source | 156,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 1,100,000Source | 2,797,000Source | 38,275,000Source | 26,004,000Source | 110,777,000Source |
| Operating Income (Loss)USD | — | — | -21,066,000Source | -17,575,000Source | -29,155,000Source | -21,811,000Source | -26,499,000Source | -21,889,000Source | -143,405,000Source | -43,897,000Source | -86,416,000Source | 14,538,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 250,000Source | 126,000Source | -5,000Source | -3,000Source | 0Source | -2,010,000Source | 606,000Source | 691,000Source | 330,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -139,495,000Source | -77,137,000Source | -238,710,000Source | 34,770,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -9,193,000Source | 287,000Source | -19,000,000Source | -609,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -35,902,000Source | -24,183,000Source | 15,769,000Source | 15,886,000Source | -39,182,000Source | -17,710,000Source | -130,302,000Source | -77,424,000Source | -219,710,000Source | 35,379,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.38Source | -1.13Source | 0.47Source | 0.51Source | -1.46Source | -0.68Source | -5.02Source | -4.48Source | -1.66Source | 0.24Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.38Source | -1.13Source | 0.46Source | 0.5Source | -1.46Source | -0.68Source | -5.02Source | -4.49Source | -1.66Source | 0.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 26,002,892Source | 21,471,408Source | 29,467,130Source | 25,980,262Source | 26,855,158Source | 25,902,650Source | 25,973,329Source | 17,276,822Source | 155,109,561Source | 144,758,555Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 26,002,892Source | 21,471,408Source | 29,860,880Source | 26,447,251Source | 26,855,158Source | 25,902,650Source | 25,973,329Source | 17,357,943Source | 155,109,561Source | 145,874,889Source |
| Interest Expense (non-operating)USD | — | — | — | 0Source | 852,000Source | 0Source | — | — | — | 0Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 300,000Source | -19,000,000Source | 16,000,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 38,000Source | -22,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -6,890,000Source | -149,600,000Source | — |
| General and Administrative ExpenseUSD | — | — | 7,716,000Source | 6,562,000Source | 8,724,000Source | 7,240,000Source | 7,114,000Source | 8,315,000Source | 31,468,000Source | 30,126,000Source | 40,581,000Source | 23,862,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,833,000Source | 3,031,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 2,100,000Source | 3,000,000Source |
| Investment Income, InterestUSD | — | — | — | — | 1,103,000Source | 1,748,000Source | 1,026,000Source | 2,015,000Source | 6,579,000Source | 7,386,000Source | — | — |
| Investment Income, NetUSD | — | — | 1,548,000Source | 2,573,000Source | — | 1,748,000Source | — | 2,015,000Source | — | — | 4,964,000Source | 2,073,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | 13,720,000Source | 13,258,000Source | — | — | -130,302,000Source | -77,424,000Source | -257,260,000Source | — |
| Nonoperating Income (Expense)USD | — | — | — | — | 44,924,000Source | 37,697,000Source | -12,683,000Source | 4,179,000Source | 3,910,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 21,518,000Source | 17,962,000Source | 29,155,000Source | 22,109,000Source | 26,577,000Source | 22,989,000Source | 146,202,000Source | 82,810,000Source | 112,420,000Source | 96,239,000Source |
| Research and Development ExpenseUSD | — | — | 13,802,000Source | 11,400,000Source | 20,431,000Source | 14,869,000Source | 19,463,000Source | 14,674,000Source | 58,034,000Source | 45,105,000Source | 71,839,000Source | 72,377,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
ef20075770_ex99-1.htm · 8-K · 2026-06-09
EX-99.1 2 ef20075770_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple Cartesian-owned, internally developed next-genera…
Read attachment ↗ef20057980_ex99-1.htm · 8-K · 2025-10-30
EX-99.1 3 ef20057980_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cartesian Therapeutics Announces Carsten Brunn, Ph. D., Named as Chairman of the Company’s Board of Directors FREDERICK, Md., October 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that Carsten Brunn, Ph. D., was named as Chairman of the Board of Directors, effective October 29, 2025. Dr.…
Read attachment ↗